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nephropathy.
Background. Type 2 diabetes is the leading cause of end-
stage renal disease (ESRD). The Reduction of Endpoints
in NIDDM with the Angiotensin II Antagonist Losartan
(RENAAL) study provided the opportunity to estimate costs
associated with ESRD by baseline albuminuria from a United
States perspective.
Methods. Costs for ESRD in patients with diabetes were
estimated by baseline albuminuria using the U.S. Renal Data
System by using the number of days each patient experienced
ESRD and the daily estimated U.S. cost of ESRD.
Results. The losartan-based antihypertensive therapy group
experienced a 28.6% (P = 0.002) reduction in the risk of the
development of ESRD compared with placebo-based conven-
tional antihypertensive therapy. The previously estimated an-
nual ESRD-related cost saving in the losartan group was $5,144
(95% CI $1,701–$8,586, P = 0.003) at 3.5 years. With the cost of
losartan, the net savings in the losartan group was estimated at
$3,522 ($143–$6,900, P = 0.041) by 3.5 years. More ESRD-free
days were observed and reduced ESRD costs estimated with
losartan-based treatment over all levels of baseline albumin-
uria.
Conclusion. Treatment with losartan in patients with type
2 diabetes and nephropathy in the RENAAL study not only
reduces the incidence of ESRD, but is also estimated from a U.S.
perspective to result in substantial cost savings over the 3.5-year
duration of the trial across all levels of baseline albuminuria.
The U.S. Renal Data System estimated that 350,000 pa-
tients in the United States experienced end-stage renal
disease (ESRD) in 1999 [1], an incidence that has almost
doubled over the last decade [2]. The leading cause of
ESRD in the United States is diabetes, which was associ-
ated with 40% of new cases of ESRD between 1994 and
1999 [1]. The prevalence of type 2 diabetes has been in-
creasing in recent years, and this is thought to be related
Key words: diabetic nephropathy, costs, end-stage renal disease.
C© 2004 by the International Society of Nephrology
to the increasing caloric intake and reduced physical ac-
tivity of the U.S. population. The number of patients re-
quiring dialysis or transplantation is expected to increase
as the number of patients with type 2 diabetes contin-
ues to grow. ESRD poses significant risks to patients, and
substantial burden to health care systems. The United
States’ Medicare ESRD program incurred $12.7 billion
in costs in 1998 alone, and these costs are expected to be
$28 billion per year by 2010 [1]. ESRD patients represent
0.5% of Medicare recipients, but account for 5% of Medi-
care expenditures [3]. Medicare payments for ESRD are
higher for patients with diabetes ($53,000/year) than for
patients without diabetes ($41,000/year) [4].
Therapies that delay the onset of ESRD can have a sub-
stantial impact on health care costs for this increasingly
prevalent disease. The landmark Reduction of Endpoints
in NIDDM with the Angiotensin II Receptor Antago-
nist Losartan (RENAAL) study evaluated outcomes and
progression of renal disease in a large cohort of patients
with type 2 diabetes, and nephropathy [5]. Treatment with
losartan significantly reduced the risk of progression to
ESRD by 28.6% (P = 0.002) and albuminuria (defined as
the urinary albumin to creatinine ratio, UACR) by 35%
(P < 0.0001) compared with placebo-based conventional
therapy. Albuminuria was the most important indepen-
dent risk factor for ESRD [6].
METHODS
The RENAAL study design and primary results have
been published previously [5]. The methods and results
for the prespecified and post hoc analyses of the costs
associated with ESRD in the RENAAL study have also
been previously reported for the United States [7]. The
longitudinal costs for ESRD in patients from the United
States with diabetes were estimated using data from the
1997–1998 U.S. Renal Data System [1]. The average costs
were estimated to be $267 per day for the first 90 days after
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the onset of ESRD, and $147 per day thereafter. The total
cost was defined as the cost associated with ESRD plus
the cost of losartan. The cost of losartan was estimated by
using the 2001 average wholesale price of losartan ($1.43
for 50 mg, and $1.95 for 100 mg) multiplied by the number
of days the patient was treated with losartan.
In this paper, we performed additional cost analyses
using comparable methods for the evaluation of baseline
albuminuria-related costs. For this purpose, we catego-
rized patients into four groups by baseline albuminuria:
<1000, 1000 to 2000, 2000 to 4000, and ≥4000 mg/g.
RESULTS
As previously reported [7], this analysis included 751
patients in the losartan-based antihypertensive therapy
group, and 762 patients in the placebo-based conven-
tional antihypertensive therapy group. After 3.5 years,
20.8% of patients in the losartan group and 27.1% of
the patients in the placebo group had developed ESRD
[28.6% (P = 0.002) reduction in the risk of development
of ESRD]. The mean ESRD days at 3.5 years were 76.1
days in the losartan group and 109.7 days in the placebo
group, a reduction of 33.6 days in the losartan group (10.9
to 56.3 days, P = 0.004). The ESRD-related cost savings
in the losartan group compared with the placebo group
at 3.5 years was $5144 ($1701 to $8586, P = 0.003). After
adding the cost of losartan, the estimated net savings in
ESRD-related costs in the losartan group compared to
the placebo group at 3.5 years was $3522 ($143 to $6900,
P = 0.041).
Categorizing patients in RENAAL by categories of
baseline albuminuria, there were 656 patients with base-
line albuminuria <1000 mg/g, 356 patients with 1000 to
2000 mg/g, 338 patients with 2000 to 4000 mg/g, and 163
patients with ≥4000 mg urinary albumin/g creatinine. In-
creasing baseline albuminuria was associated with in-
creasing risk of the ESRD end point, with more than
15 times the risk for ESRD in patients with urinary al-
bumin to creatinine ratios ≥4000 mg/g versus those with
<1000 mg/g (Fig. 1A). Treatment with losartan reduced
albuminuria, and this was associated with fewer ESRD
days. The degree of albuminuria also impacted the num-
ber of ESRD-free days (Fig. 1B). More ESRD-free days
were observed in the losartan-treated group over all lev-
els of albuminuria, but were particularly evident in pa-
tients with the highest levels of baseline urinary albumin
excretion (Fig. 1B). ESRD-related costs were estimated
as being lower in the losartan group over the 3.5 years
of study across all levels of baseline albuminuria, with
the greatest absolute cost savings seen in patients with
the greatest degree of albuminuria (Fig. 2A). Even after
losartan costs were added, net savings were still realized
across all levels of albuminuria, with the greatest absolute
savings observed in patients with the greatest degree of
baseline albuminuria (Fig. 2B).
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Fig. 1. (A) Relationship between baseline albuminuria and hazard ra-
tios for ESRD in the losartan group, relative to baseline albuminuria
<1000 mg/g. (B) Number of ESRD days saved per patient at 3.5 years by
baseline albuminuria in the losartan group compared with the placebo
group.
DISCUSSION
The RENAAL study showed that patients with type 2
diabetes and nephropathy are at a significantly lower risk
of developing ESRD regardless of baseline albuminuria
when they are treated with losartan-based therapy. This is
an important public health finding not only in the United
States [7], but also in many other countries [8, 9], in light
of the fact that there were significant ESRD-related cost
savings estimated with losartan treatment in these pa-
tients with diabetic nephropathy. Reduction of the risk of
progression of type 2 diabetic nephropathy to ESRD is
important because of the significant and substantial risks
to patients, and also the burden this devastating compli-
cation of type 2 diabetes places on health care systems.
As the prevalence and incidence of type 2 diabetes [10],
diabetic renal disease and failure grow [11], funding and
facilities will be further strained. The ESRD Medicare
costs, already $12.7 billion in 1998, are expected to more
than double by 2010 [1].
Early detection and treatment of diabetes and its renal
complications are important to reduce the patient suf-
fering and economic burden of ESRD. The RENAAL
study showed the benefits of losartan beyond blood pres-
sure control. This is a very important consideration for
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Fig. 2. ESRD-related costs and cost savings
(U.S. dollars) associated with baseline albu-
minuria. (A) ESRD-related costs per patient
at 3.5 years. (B) ESRD-related cost savings
and net costs savings at 3.5 years in the losar-
tan group compared with the placebo group.
treatment of patients with diabetic nephropathy, which
should also include appropriate lifestyle changes,
glycemic control, cholesterol control, and blood pressure
control.
Treatment with losartan in patients with type 2 diabetes
and nephropathy in the RENAAL study not only reduced
the incidence of ESRD, but also was estimated to result
in substantial cost savings within the trial, regardless of
baseline albuminuria.
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